MOTS-C 20

MOT-C (20 mg Vial) Dosage Protocol

MOTS-C (20 mg Vial) Dosage Protocol

MOTS-c is a 16–amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation^[1]^[2]. Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and counters age-related metabolic decline^[1]^[4]. No clinical trials have been completed in humans to date^[8]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.

Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	200 mcg (0.2 mg)	3 units (0.03 mL)
Weeks 3–4	400 mcg (0.4 mg)	6 units (0.06 mL)
Weeks 5–6	600 mcg (0.6 mg)	9 units (0.09 mL)
Weeks 7–8	800 mcg (0.8 mg)	12 units (0.12 mL)
Weeks 9–10+	1,000 mcg (1.0 mg)	15 units (0.15 mL)

Frequency: Inject once daily subcutaneously^[7]. Stay at each dose level for approximately 2 weeks before increasing, and monitor for any adverse reactions^[7].

For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake vigorously).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use within 7 days for optimal potency^[7].

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (MOTS-C, 20 mg each):
- 8 weeks ≈ 2 vials
- 12 weeks ≈ 3 vials
- 16 weeks ≈ 5 vials
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Concise summary of the once‑daily regimen.

Goal: Support metabolic homeostasis, insulin sensitivity, and age-related physical performance based on preclinical evidence^[1]^[2]^[4].
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 200–1,000 mcg daily with gradual titration over 10 weeks.
Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.

Suggested daily titration approach based on animal-to-human extrapolation.

Start: 200 mcg daily for 2 weeks.
Titration: Increase by ~200 mcg every 2 weeks: 400 mcg (Weeks 3–4), 600 mcg (Weeks 5–6), 800 mcg (Weeks 7–8).
Target: Up to 1,000 mcg (1.0 mg) daily by Weeks 9–10+ if well tolerated^[7].
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Any consistent time; rotate injection sites.

Proper storage preserves peptide quality and potency.

Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; include desiccant if available to minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); peptide degrades rapidly at room temperature (~25% activity loss after 24 hours at 4 °C)^[7]. Use within 7 days for best potency.
Aliquoting: Prepare single-use aliquots and freeze at −20 °C (−4 °F) if needed; avoid freeze–thaw cycles.
Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a sharps container^[11].
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy^[11].
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose, injection site, and any observations to maintain consistency.
Discontinue use and consult a medical professional if any concerning symptoms arise.

MOTS-c functions as a metabolic “stress signal” that helps optimize energy usage during nutrient stress or exercise^[2]. Its primary mechanism is AMPK activation through inhibition of the folate cycle, causing accumulation of AICAR (an AMP analog)^[1]^[2]. Activated AMPK shifts cells into an energy-efficient mode – enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis^[2].

MOTS-c can also translocate to the cell nucleus under stress conditions and upregulate antioxidant and stress-response genes^[2]. This retrograde signaling from mitochondria to nucleus increases expression of cytoprotective enzymes, helping cells cope with oxidative stress. Research indicates MOTS-c may also modulate mTOR and inflammatory pathways, contributing to lifespan and healthspan effects^[10]. Its actions resemble those of exercise and metformin at a cellular level^[2], making it of great interest for metabolic disorders, obesity, and aging research.

Observations from preclinical literature (no human clinical trials completed to date)^[8]:

Metabolic Health: Improves insulin sensitivity and glucose metabolism in mouse models; prevents diet-induced insulin resistance^[1]^[7].
Weight & Fat Reduction: Prevents obesity and reduces visceral fat in obese mice through increased energy expenditure and fat oxidation^[1]^[7].
Post-Menopausal Metabolism: Mitigates metabolic decline in ovariectomized mice; prevents menopause-related fat gain and insulin resistance^[3].
Physical Performance: Enhances exercise capacity and counters age-related frailty; old mice ran 2× longer on treadmill tests^[4]^[7].
Organ Protection: Reduces liver fat accumulation, improves cardiac function, and may support cognitive function in preliminary studies^[2]^[7].
Bone & Immunity: Promotes osteoblast activity, inhibits osteoclast formation; modulates immune aging and protects pancreatic islet cells in autoimmune diabetes models^[5]^[10].
Safety: No adverse effects reported in preclinical studies; human tolerability unknown. A modified analog (CB4211) showed good tolerability in a Phase 1 trial^[7].

Note: These benefits have been demonstrated only in controlled research settings (mice or cells). Translation to humans requires clinical studies.

Complementary strategies for best outcomes based on MOTS-c’s metabolic mechanisms.

Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity to reinforce metabolic adaptations and AMPK signaling^[4]^[8].
Prioritize sleep (7–9 hours) and stress management to support mitochondrial health and recovery.
Consider intermittent fasting or caloric restriction, which may synergize with MOTS-c’s AMPK-mediated effects.

General subcutaneous guidance from clinical best‑practice resources^[9]^[11]:

Clean the vial stopper and skin with alcohol; allow to dry completely.
Pinch a skinfold; insert the needle at 90° (45° if very lean) into subcutaneous tissue^[11].
Do not aspirate for subcutaneous injections; inject slowly and steadily over a few seconds^[9].
Withdraw needle at the same angle; apply gentle pressure if bleeding occurs (do not rub).
Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to avoid irritation and lipohypertrophy^[11].
Dispose of used syringes immediately in a proper sharps container (never reuse needles)^[11].

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-c is an experimental compound; no clinical trials have been completed in humans. Always consult qualified healthcare providers before starting any new therapy.

References

— The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.)

— Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.)

— MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction (Lu H, Wei M, Zhai Y, et al.)

— MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.)

— Role of MOTS-c in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.)

— MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases (Mohtashami Z, Singh MK, Salimiaghdam N, et al.)

— MOTS-c (Cognitive Vitality Profile) – Alzheimer’s Drug Discovery Foundation (ADDF)

— What is the MOTS-c peptide? – U.S. Anti-Doping Agency education article

— Subcutaneous route technique (angle, site selection, no aspiration)

— Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Kong BS, Lee H, L’Yi S, et al.)

— Subcutaneous (SQ) injections – Patient instructions for proper technique

— Literature review of factors influencing subcutaneous injection pharmacology

— MOTS-C (20 mg) product page (quality and batch documentation)

Mechanism Breakdown — 3rd Party Analysis

This video provides an external overview on MOT-C

External Source

Titration schedule.

Standard research titration model. Adjust under qualified clinical observation only. Not for human therapeutic use.

Phase 01

Wk 1 — 4

6 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

12 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

15 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

20 units

Once daily

Optional research extension

Research use only.

Reta20 is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Handling must be performed by qualified personnel in compliance with applicable institutional and jurisdictional safety standards. The information contained on this protocol sheet is provided for educational and reference purposes only and does not constitute medical advice.

Not for human use
Store at 2–8 °C, protected from light

Reconstitute under aseptic conditions
Document all research observations

Blue Tier Catalogue

Explore the full British Dragon research line.

Premium-tier compounds engineered for serious metabolic, longevity and performance research programs.

MOTS-C 20

MOT-C (20 mg Vial) Dosage Protocol

MOTS-C (20 mg Vial) Dosage Protocol

Table of Contents

Quickstart Highlights

Dosing & Reconstitution Guide

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Reconstitution Steps

Supplies Needed

Protocol Overview

Dosing Protocol

Storage Instructions

Important Notes

How This Works

Potential Benefits & Side Effects

Lifestyle Factors

Injection Technique

Video

Important Note

References

Mechanism Breakdown — 3rd Party Analysis

Titration schedule.

Phase 01

Wk 1 — 4

6 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

12 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

15 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

20 units

Once daily

Optional research extension

Research use only.

Blue Tier Catalogue

Explore the full British Dragon research line.